The American Medical Association (AMA) had pushed for the CVS–Aetna merger to be blocked because of the increasing body of literature that shows consolidation results in more expensive care with no increase in quality, said Barbara L. McAneny, MD, president of the AMA.
The American Medical Association (AMA) had pushed for the CVS—Aetna merger to be blocked because of the increasing body of literature that shows consolidation results in more expensive care with no increase in quality, said Barbara L. McAneny, MD, president of the AMA.
Transcript
How do you view the vertical integration that has been happening, such as the CVS—Aetna merger?
We had actually requested through the California Department of Insurance and through other testimony that the CVS—Aetna merger not be allowed to take place. We’re appreciative that they at least took the [Medicare] Part D plan away from Aetna, because that was the most egregious conflict of interest.
However, there’s an increasing body of literature that shows that consolidation—either horizontal, where it’s a bunch of hospitals or a bunch of health plans consolidating, or vertical, where it’s health plans and hospitals and pharmacies and other things consolidating—increases their market dominance, which allows them to negotiate higher prices for the exact same service they were delivering before.
So, consolidation has been shown to increase the cost of healthcare, decrease the choice that patients have, and the choice that doctors have, and, if you’re lucky, the quality stays the same.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More